ClinicalTrials.Veeva

Menu

Factors of Steroid Dependency in Idiopathic Nephrotic Syndrome (NEPHROVIR-2)

A

Assistance Publique - Hôpitaux de Paris

Status

Completed

Conditions

Idiopathic Nephrotic Syndrome

Treatments

Genetic: DNA chip dedicated to the pharmacogenetic of steroids

Study type

Observational

Funder types

Other

Identifiers

NCT01609426
NI11021
AOM 11002 (Other Identifier)

Details and patient eligibility

About

The primary purpose of the study is to identify the factors of steroid dependency in childhood idiopathic nephrotic syndrome. The steroid dependency is defined by a relapse of nephrotic syndrome within the 3 weeks that follow the withdrawal of steroid therapy after the first manifestation. Different clinical and biological factors will be analyzed: age of first manifestation, delay of remission, ethnicity, and preceding viral infection, geolocalization in the Parisian area, genoprevalence of herpes viruses and polymorphisms in the genes involved in the response to steroid therapy.

Full description

Patients with a steroid dependent nephrotic syndrome will be compared to those with a non steroid dependent form of nephrotic syndrome at the end of the first manifestation. An additional blood volume will be sampled in patients and controls during a scheduled biological check-up for the initial disease. Genetics factors will be checked using a DNA chips devoted to the response to steroid therapy and viral genome of EBV, CMV, HHV7 will be searched for using PCR reaction in total blood DNA extract.

Enrollment

351 patients

Sex

All

Ages

6 months to 16 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • children below 16 years
  • first manifestation of nephrotic syndrome
  • steroid sensitivity according to the recommendations of the french "pediatric society nephrology"

Exclusion criteria

  • patients who don't stay in Paris during the study

Trial design

351 participants in 1 patient group

children with idiopathic nephrotic syndrome
Description:
children below 16 years of age with a steroid dependent nephrotic syndrome
Treatment:
Genetic: DNA chip dedicated to the pharmacogenetic of steroids

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems